Efficacy and influencing factors of piperacillin sodium tazobactam sodium combined with moxifloxacin in the treatment of severe pneumonia in the elderly.

BACKGROUND

Elderly patients with severe pneumonia face elevated mortality from complex, often resistant, polymicrobial infections.

OBJECTIVE

This investigation aimed at assessing the efficacy and determinants of PTZ plus moxifloxacin for severe elderly pneumonia.

METHODS

Retrospectively, this study evaluated 120 elderly severe pneumonia patients (2021-2024), grouped by treatment: Control (n=60): IV piperacillin-tazobactam (PTZ), 4.5g q6h; observation (n=60): PTZ + daily moxifloxacin 400mg. Primary outcomes pathogen resistance/clearance; secondary: 30-day mortality, readmission, CURB-65, ventilation duration, serum biomarkers. Logistic regression identified mortality factors; adverse events were recorded.

RESULTS

Baseline characteristics were comparable between groups (P>0.05). The observation group demonstrated superior primary outcomes (P<0.001) and pathogen clearance (P=0.013). No significant intergroup differences were found in secondary outcomes, including mortality, readmission, PLT and adverse events. Post-treatment CURB-65≥3, PCT and CRP significantly correlated with 30-day mortality (all P<0.001).

CONCLUSION

The moxifloxacin-PTZ regimen enhanced microbial clearance without affecting survival, readmission, or adverse event rates, supporting its targeted clinical use.